A small city in Brazil tests a nationwide vaccination against China, and the number of deaths from the new crown drops 95%

Trainee Reporter | Hu Xianhe

Editor | Zhai Ruimin

On the afternoon of May 31, 2021, the State of Sao Paulo, Brazil, announced the results of the evaluation study on the use of the new crown vaccine from China Science and Technology conducted in Serrana, a small town in southeastern Brazil
.

The results of the study showed that after the vaccination, the number of deaths caused by the new crown virus in the region has dropped by 95%, the number of symptomatic cases has dropped by 80%, and the number of hospitalizations has dropped by 86%

Serana has a permanent population of approximately 45,000 (an adult population of 28,000), which is one of the areas with the highest rate of new coronary pneumonia infections in São Paulo State
.

The town’s vaccination began on February 17, local time, and lasted for two months

In the study, the town was divided into 25 areas and divided into four groups
.

Four weeks before the start of the project, one group of areas will be vaccinated with the first dose of Kellyf vaccine every week, and as many eligible adults will be vaccinated in the covered areas

Wang Xuanyi, a professor at the Institute of Biomedical Research at Fudan University, said that the available data shows that the incidence of severe illness (hospitalization and death) in Serrana dropped rapidly after the second dose of vaccination started, while other vaccines in São Paulo state had low coverage rates.
The region did not show this trend
.

Kexing said that the research results show that the large-scale vaccination not only protects the vaccinators themselves, but also protects the surrounding non-vaccinators
.

In addition, even in high-spread areas, the epidemic can be controlled by vaccination

The mass vaccination project carried out by Serana is called "Plan S"
.

The "S Project" (S Project) is a research project proposed by the Butan Tan Institute, an authoritative Brazilian medical institution, in 2020, which aims to carry out research on the effectiveness of the new crown vaccine through large-scale population vaccination

Previously, Kexing Company had cooperated with Basilibutan in the evaluation of the effect of the new crown vaccine, and jointly advanced the phase III clinical trial of the new crown vaccine Kellyf, which was confirmed by conducting research among 12,000 medical staff in Brazil.
The effectiveness and safety of the company's vaccines
.

Kexing Holdings is one of the main suppliers of domestic new crown vaccine
.

The company said on June 1 that as of May 31, Kexing has supplied more than 600 million doses of the new crown vaccine to China and nearly 40 other countries and regions around the world.